Palatin Technoloes, Inc. announced plans to initiate a clinical study of melanocortin 4 receptor (MC4R) agonist, bremelanotide, an FDA approved product and 100% owned by Palatin, in combination with a Glucagon Like Peptide-1 (GLP-1) agonist, in obese patients in the first quarter of calendar year 2024. In addition, Palatin announced a poster presentation of preclinical data, entitled Melanocortin receptor 4 agonist PL8905 in Combination with Glucagon Like Peptides-1 Produces Synergistic Weight Loss, Reduced Food intake, and Greater Glucose Control in Diet-Induced Obese (DIO) rats (Dodd et al.) at the Peptide Therapeutics Symposium, October 16-17, 2023 in La Jolla, CA. Combination drug therapy will be a key part of improving the overall health and quality of life for obese patients.

The Peptide Therapeuticsposium poster presented data evaluating the selective MCR4 agonist PL8905 from preclinical studies in which diet-induced obese animals were treated for 5 days with vehicle control, subcutaneous PL8905 alone and in combination with continuous infusion of a GLP-1 agonist. Vecle c control and infused GLP-1 alone slightly increased body weight.